52 Weeks Double-blind, Double-dummy, Randomized Placebo-controlled Trial to Evaluate Safety, Efficacy and Tolerability of Remibrutinib in Comparison to Placebo With Omalizumab as Active Control in Adult Patients With CSU and Inadequate Response to H1-antihistamine.
Condition: Chronic Spontaneous Urticaria Interventions: Drug: Remibrutinib; Drug: Placebo to remibrutinib; Drug: Placebo to omalizumab; Drug: Omalizumab Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Biologics and Sublingual Immunotherapy
Condition: Asthma, Allergic Intervention: Biological: omalizumab Sponsors: Medical University of Silesia; Centrum Medyczne Andrzej Bożek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
A Single Dose, Phase 1 Study of YH35324 in Patients With Various Allergic Diseases
Conditions: Allergic Disease; Chronic Spontaneous Urticaria; Chronic Inducible Urticaria; Cold Urticaria Interventions: Drug: YH35324; Drug: Omalizumab; Drug: Placebo Sponsor: Yuhan Corporation Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials
